Search Results
Valrocemide 10 mg | 99.90%
TargetMol
Valrocemide, also known as TV-1901, is an antiepileptic drug (AED). Valrocemide has a broad spectrum of anticonvulsant activity and promising potential as a new AED. Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy.
More Information Supplier PageValrocemide 100 mg | 99.90%
TargetMol
Valrocemide, also known as TV-1901, is an antiepileptic drug (AED). Valrocemide has a broad spectrum of anticonvulsant activity and promising potential as a new AED. Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy.
More Information Supplier PageIMR-1A 5 mg | Purity Not Available
TargetMol
IMR-1A is the metabolite of IMR-1 which is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μMol/L.
More Information Supplier PageIMR-1A 1 mg | Purity Not Available
TargetMol
IMR-1A is the metabolite of IMR-1 which is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μMol/L.
More Information Supplier PageIMR-1A 10 mg | Purity Not Available
TargetMol
IMR-1A is the metabolite of IMR-1 which is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μMol/L.
More Information Supplier PageOcaperidone 5 mg | 99.94%
TargetMol
Ocaperidona (Ocaperidone), a very high affinity dopamine D2 antagonist.
More Information Supplier PageOcaperidone 50 mg | 99.94%
TargetMol
Ocaperidona (Ocaperidone), a very high affinity dopamine D2 antagonist.
More Information Supplier PageOcaperidone 25 mg | 99.94%
TargetMol
Ocaperidona (Ocaperidone), a very high affinity dopamine D2 antagonist.
More Information Supplier PageValrocemide 50 mg | 99.90%
TargetMol
Valrocemide, also known as TV-1901, is an antiepileptic drug (AED). Valrocemide has a broad spectrum of anticonvulsant activity and promising potential as a new AED. Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy.
More Information Supplier Page
